Stem cells heal injured and diseased tissues through the paracrine release of exosomes and other soluble factors, collectively known as the cell’s secretome. Over 300 factors in the secretome mediate its anti-inflammatory, anti-fibrotic, pro-angiogenic, and antioxidant effects.

Our lead clinical asset, STM-01, is a neonatal cardiac progenitor cell (nCPC) in Phase 1 clinical trials in heart failure with preserved ejection fraction (HFpEF) and dilated cardiomyopathy (DCM).

Our lead preclinical asset, STM-21, is the secretome from STM-01. We are developing STM-21 for neurological conditions including amyotrophic lateral sclerosis (ALS) and diabetic neuropathy, and for burns and other inflammatory conditions of the skin.

*Investigator-sponsored study at Emory/CHOA funded by the Marcus Foundation